Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Oncolytics Biotech Inc.

  • Matt Coffey, Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and adaptive immune responses. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.

  • Date:Monday, February 11
  • Time:2:30 PM - 2:45 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Submission ID:23296
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Financial community update
  • Company Website:https://www.oncolyticsbiotech.com
  • Company HQ City:Calgary
  • Company HQ State:Alberta
  • Company HQ Country:Canada
  • Ticker:ONCY
  • Exchange:Nasdaq
  • CEO/Top Company Official:Dr. Matt Coffey
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:pelareorep
  • Development Phase of Primary Product:Phase II
Speakers
Matt Coffey
Oncolytics Biotech Inc.
Back